47 Pathologists enhance interpretation of automated multiplex immunohistochemistry assays in cancer immunotherapy trials
Emmanuel Pacia, Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Evelyn Diaz(Navidea Biopharmaceuticals (United States)), Alexander Savchenko(Precision for Medicine (United States)), Bashar Dabbas(Lineage Cell Therapeutics (United States)), Shabnam Tangri(Navidea Biopharmaceuticals (United States)), Nathan Roscoe(Navidea Biopharmaceuticals (United States)), Beiru Chen(Lineage Cell Therapeutics (United States)), Xun Li, Ju Young Kim(Navidea Biopharmaceuticals (United States)), Jason D. Hughes(University of California, Irvine), Margaret E. McLaughlin(Novartis (Switzerland)), Thai H. Tran(Navidea Biopharmaceuticals (United States))
Cited by 0
Related Papers
Restoration of p53 function leads to tumour regression in vivo
|Nature|2007|1.8k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
|Science|2014|844
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833